Osteoprotegerin (OPG) and RANKL expression and distribution in developing human craniomandibular joint

被引:27
作者
Carda, C
Silvestrini, G
de Ferraris, MEG
Peydró, A
Bonucci, E
机构
[1] Univ Valencia, Sch Med, Dept Pathol, Valencia 46010, Spain
[2] Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy
[3] Natl Univ Cordoba, Catedra Histol B, Sch Dent, Cordoba, Argentina
关键词
OPG; RANKL; development; craniomandibular joint;
D O I
10.1016/j.tice.2005.03.002
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
During embryogenesis the bone tissue of craniomandibular joint (CMJ) is formed through two pathways: intramembranous ossification and endochondral ossification. The development process is under the control of regulatory factors. The osteoprotegerin (OPG) and the receptor activator of nuclear factor (NF)-kappa B ligand are key regulators of osteoclastogenesis. The aim of this study is the localization of OPG and RANKL mRNA and protein in the foetal CMJ by immunohistochemistry (IHC) and in situ hybridization (ISH). The main results were: OPG and RANKL mRNA and protein were co-localized in the same cell types; OPG and RANKL were specially immunolocated in osteogenic cells; immunolabeling was often seen in the nucleus and cytoplasm of otherwise negative hypertrophic chondrocytes; IHC and ISH labeling decreased from proliferative to hypertrophic chondrocytes; early osteocytes showed dual protein expression and some of the mature osteocytes were ISH-negative; periosteal osteoclasts and chondroclasts were mostly stained by IHC and variably labeled by ISH; the new bone matrix and trabecular borders showed intense immunolabeling. The co-expression of OPG and RANKL in the same bone cell types confirms their strictly coupled action in the regulation of bone metabolism in the CMJ development and their extracellular presence in the new bone matrix and trabecular borders suggests a local regulatory role. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:247 / 255
页数:9
相关论文
共 23 条
  • [1] A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
    Anderson, DM
    Maraskovsky, E
    Billingsley, WL
    Dougall, WC
    Tometsko, ME
    Roux, ER
    Teepe, MC
    DuBose, RF
    Cosman, D
    Galibert, L
    [J]. NATURE, 1997, 390 (6656) : 175 - 179
  • [2] Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation
    Atkins, GJ
    Haynes, DR
    Geary, SM
    Loric, M
    Crotti, TN
    Findlay, DM
    [J]. BONE, 2000, 26 (06) : 653 - 661
  • [3] Osteoprotegerin and rank ligand expression in prostate cancer
    Brown, JM
    Corey, E
    Lee, ZD
    True, LD
    Yun, TJ
    Tondravi, M
    Vessella, RL
    [J]. UROLOGY, 2001, 57 (04) : 611 - 616
  • [4] Clonal endothelial cells produce humoral factors that inhibit osteoclast-like cell formation in vitro
    Chikatsu, N
    Takeuchi, Y
    Fukumoto, S
    Yano, K
    Fujita, N
    Tsuruo, T
    Fujita, T
    [J]. ENDOCRINE JOURNAL, 2002, 49 (04) : 439 - 447
  • [5] Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques
    Dhore, CR
    Cleutjens, JPM
    Lutgens, E
    Cleutjens, KBJM
    Geusens, PPM
    Kitslaar, PJEHM
    Tordoir, JHM
    Spronk, HMH
    Vermeer, C
    Daemen, MJAP
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (12) : 1998 - 2003
  • [6] Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene
    Enomoto, H
    Shiojiri, S
    Hoshi, K
    Furuichi, T
    Fukuyama, R
    Yoshida, CA
    Kanatani, N
    Nakamura, R
    Mizuno, A
    Zanma, A
    Yano, K
    Yasuda, H
    Higashio, K
    Takada, K
    Komori, T
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (26) : 23971 - 23977
  • [7] The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption
    Hofbauer, LC
    Khosla, S
    Dunstan, CR
    Lacey, DL
    Boyle, WJ
    Riggs, BL
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (01) : 2 - 12
  • [8] Expression profiles of receptor activator of nuclear factor κB ligand, receptor activator of nuclear factor κB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones
    Ikeda, T
    Utsuyama, M
    Hirokawa, K
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (08) : 1416 - 1425
  • [9] Expression of osteoprotegerin in synovial tissue and degradation of articular cartilage: Comparison with arthroscopic findings of temporomandibular joint disorders
    Kaneyama, K
    Segami, N
    Sato, J
    Nishimura, M
    Yoshimura, H
    [J]. ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS, 2003, 96 (03): : 258 - 262
  • [10] Localization of RANKL (Receptor activator of NFκB ligand) mRNA and protein in skeletal and extraskeletal tissues
    Kartsogiannis, V
    Zhou, H
    Horwood, NJ
    Thomas, RJ
    Hards, DK
    Quinn, JMW
    Niforas, P
    Ng, KW
    Martin, TJ
    Gillespie, MT
    [J]. BONE, 1999, 25 (05) : 525 - 534